These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1042 related articles for article (PubMed ID: 3114621)
1. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures. Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621 [TBL] [Abstract][Full Text] [Related]
2. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. Itoh K; Tilden AB; Balch CM J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648 [TBL] [Abstract][Full Text] [Related]
3. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels. Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633 [TBL] [Abstract][Full Text] [Related]
4. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood. Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745 [TBL] [Abstract][Full Text] [Related]
5. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
7. Generation of lymphokine-activated killer cell activity from human thymocytes. Ramsdell FJ; Golub SH J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246 [TBL] [Abstract][Full Text] [Related]
8. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. Bolhuis RL; Roozemond RC; van de Griend RJ J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649 [TBL] [Abstract][Full Text] [Related]
9. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen. Phillips JH; Lanier LL J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407 [TBL] [Abstract][Full Text] [Related]
10. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex. Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151 [TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
12. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. Itoh K; Tilden AB; Kumagai K; Balch CM J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475 [TBL] [Abstract][Full Text] [Related]
13. CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis. De Maria A; Malnati M; Moretta A; Pende D; Bottino C; Casorati G; Cottafava F; Melioli G; Mingari MC; Migone N Eur J Immunol; 1987 Dec; 17(12):1815-9. PubMed ID: 2961576 [TBL] [Abstract][Full Text] [Related]
14. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. Whiteside TL; Wang YL; Selker RG; Herberman RB Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433 [TBL] [Abstract][Full Text] [Related]
15. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Chang WC; Hsiao MH; Pattengale PK Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400 [TBL] [Abstract][Full Text] [Related]
16. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457 [TBL] [Abstract][Full Text] [Related]
17. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. Lanier LL; Benike CJ; Phillips JH; Engleman EG J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216 [TBL] [Abstract][Full Text] [Related]
18. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. Lanier LL; Le AM; Civin CI; Loken MR; Phillips JH J Immunol; 1986 Jun; 136(12):4480-6. PubMed ID: 3086432 [TBL] [Abstract][Full Text] [Related]
19. Activation through CD3 molecule leads to clonal expansion of all human peripheral blood T lymphocytes: functional analysis of clonally expanded cells. Weber WE; Buurman WA; Vandermeeren MM; Raus JC J Immunol; 1985 Oct; 135(4):2337-42. PubMed ID: 3875651 [TBL] [Abstract][Full Text] [Related]
20. Induction of NK-like activity in T cells by IL-2/anti-CD3 is linked to expression of a new antitumour receptor with specificity for acetylated mannose. Zollner TM; Zhu HG; Anderer FA Anticancer Res; 1993; 13(4):923-30. PubMed ID: 8352560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]